Nanocages displaying SIRP gamma clusters combined with prophagocytic stimulus of phagocytes potentiate anti-tumor immunity
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Yoonjeong | - |
dc.contributor.author | Nam, Gi-Hoon | - |
dc.contributor.author | Kim, Gi Beom | - |
dc.contributor.author | Kim, Seohyun | - |
dc.contributor.author | Kim, Yoon Kyoung | - |
dc.contributor.author | Kim, Seong A. | - |
dc.contributor.author | Kim, Ha-Jeong | - |
dc.contributor.author | Lee, Eun Jung | - |
dc.contributor.author | Kim, In-San | - |
dc.date.accessioned | 2022-02-24T18:40:53Z | - |
dc.date.available | 2022-02-24T18:40:53Z | - |
dc.date.created | 2022-02-07 | - |
dc.date.issued | 2021-09 | - |
dc.identifier.issn | 0929-1903 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/136771 | - |
dc.description.abstract | Antigen-presenting cells (APCs), including macrophages and dendritic cells (DCs), play a crucial role in bridging innate and adaptive immunity; thereby, innate immune checkpoint blockade-based therapy is an attractive approach for the induction of sustainable tumor-specific immunity. The interaction between the cluster of differentiation 47 (CD47) on tumor and signal-regulatory protein alpha (SIRP alpha) on phagocytic cells inhibits the phagocytic function of APCs, acting as a "don't eat me" signal. Accordingly, CD47 blockade is known to increase tumor cell phagocytosis, eliciting tumor-specific CD8(+) T-cell immunity. Here, we introduced a nature-derived nanocage to deliver SIRP gamma for blocking of antiphagocytic signaling through binding to CD47 and combined it with prophagocytic stimuli using a metabolic reprogramming reagent for APCs (CpG-oligodeoxynucleotides). Upon delivering the clustered SIRP gamma variant, the nanocage showed enhanced CD47 binding profiles on tumor cells, thereby promoting active engulfment by phagocytes. Moreover, combination with CpG potentiated the prophagocytic ability, leading to the establishment of antitumorigenic surroundings. This combination treatment could competently inhibit tumor growth by invigorating APCs and CD8(+) T-cells in TMEs in B16F10 orthotopic tumor models, known to be resistant to CD47-targeting therapeutics. Collectively, enhanced delivery of an innate immune checkpoint antagonist with metabolic modulation stimuli of immune cells could be a promising strategy for arousing immune responses against cancer. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGERNATURE | - |
dc.subject | SIGNAL-REGULATORY PROTEIN | - |
dc.subject | CD47 BLOCKADE | - |
dc.subject | CPG-DNA | - |
dc.subject | CELLS | - |
dc.subject | ALPHA | - |
dc.subject | RECEPTORS | - |
dc.subject | TARGET | - |
dc.subject | MACROPHAGES | - |
dc.subject | ACTIVATION | - |
dc.subject | TLR | - |
dc.title | Nanocages displaying SIRP gamma clusters combined with prophagocytic stimulus of phagocytes potentiate anti-tumor immunity | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, In-San | - |
dc.identifier.doi | 10.1038/s41417-021-00372-y | - |
dc.identifier.scopusid | 2-s2.0-85111711581 | - |
dc.identifier.wosid | 000681277300001 | - |
dc.identifier.bibliographicCitation | CANCER GENE THERAPY, v.28, no.9, pp.960 - 970 | - |
dc.relation.isPartOf | CANCER GENE THERAPY | - |
dc.citation.title | CANCER GENE THERAPY | - |
dc.citation.volume | 28 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 960 | - |
dc.citation.endPage | 970 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Genetics & Heredity | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Genetics & Heredity | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | ALPHA | - |
dc.subject.keywordPlus | CD47 BLOCKADE | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | CPG-DNA | - |
dc.subject.keywordPlus | MACROPHAGES | - |
dc.subject.keywordPlus | RECEPTORS | - |
dc.subject.keywordPlus | SIGNAL-REGULATORY PROTEIN | - |
dc.subject.keywordPlus | TARGET | - |
dc.subject.keywordPlus | TLR | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.